Treatment Adherence And Persistence Among HIV-1 Patients Newly Starting Treatment

References

• Department of Health and Human Services. What is HIV/aids? Available from: https://www.aids.gov/hiv-aids-basics/hiv-aids-101/what-is-hiv-aids/ Accessed 101, 2017.
   Google Scholar
• Centers for Disease Control and Prevention. HIV in the United States: at a glance. Available from: https://www.cdc.gov/hiv/statistics/overview/ataglance.html Accessed 101, 2017.
   Google Scholar
• HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS. 2010;24(1):123–137. doi:10.1097/QAD.0b013e328332428319770621
   PubMed Web of Science ®Google Scholar
• Lesko C, Cole S, Hall H, et al. The effect of antiretroviral therapy on all-cause mortality, generalized to persons diagnosed with HIV in the USA, 2009–11. Int J Epidemiol. 2016;45(1):140–150. doi:10.1093/ije/dyv35226772869
   PubMed Web of Science ®Google Scholar
• Murphy E, Collier A, Kalish L, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001;135(1):17. doi:10.7326/0003-4819-135-11-200112040-0001111434728
   PubMed Web of Science ®Google Scholar
• Gallant J, Brunetta J, Crofoot G et al. Efficacy and safety of switching to simpler single-tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovirAlafenamide (E/C/F/TAF) in HIV-1/hepatitis B coinfected adults in North America and Japan (NCT02071082): week 48 results [Poster WELBPA13]. Vancouver: 8th IAS Conference on HIV Pathogenesis, Treatment andPrevention 19–22.
   Google Scholar
• Lee F, Amin J, Carr A. Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks’ follow-up. PLoS One. 2014;9(5):e97482. doi:10.1371/journal.pone.009748224830290
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf Accessed October 1, 2017.
   Google Scholar
• Cramer J, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–47. doi:10.1111/j.1524-4733.2007.00213.x18237359
   PubMed Web of Science ®Google Scholar
• Bansi-Matharu L, Rodriguez LG, Cole SR, et al. Risk factors for Antiretroviral Therapy (ART) discontinuation in a large multinational trial of early ART initiators. AIDS. 2019;33(8):1385–1390. doi:10.1097/QAD.000000000000221030932953
   PubMed Web of Science ®Google Scholar
• Scott Sutton S, Magagnoli J, Hardin J. Impact of pill burden on adherence, risk of hospitalization, and viral suppression in patients with HIV infection and AIDS receiving antiretroviral therapy. Pharmacotherapy. 2016;36(4):385–401. doi:10.1002/phar.172826923931
   PubMed Web of Science ®Google Scholar
• Portsmouth S, Osorio J, McCormick K, Gazzard B, Moyle G. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med. 2005;6(3):185–190. doi:10.1111/j.1468-1293.2005.00287.x15876285
   PubMed Web of Science ®Google Scholar
• Gardner E, Burman W, Maravi M, Davidson A. Selective drug taking during combination antiretroviral therapy in an unselected clinic population. JAIDS. 2005;40(3):294–300. doi:10.1097/01.qai.0000182229.84182.0616249703
   PubMed Web of Science ®Google Scholar
• Hanna DB, Hessol NA, Golub ET, et al. Increase in single-tablet regimen use and associated improvements in adherence-related outcomes in HIV-infected women. J Acquired Immune Deficiency Syndrome. 2014;65(5):587–596. doi:10.1097/QAI.0000000000000082
   PubMed Web of Science ®Google Scholar
• Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects Patient Prefer Adherence. 2010:115–125.
   Google Scholar
• Bangsberg D, Ragland K, Monk A, Deeks S. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS. 2010;24(18):2835–2840. doi:10.1097/QAD.0b013e328340a20921045636
   PubMed Web of Science ®Google Scholar
• Armstrong B, Chan D, Stewart M, Fagan D, Smith D. Single tablet regimen usage and efficacy in the treatment of HIV infection in Australia. AIDS Res Treat. 2015;2015:1–5.
   Google Scholar
• Cooke C, Lee H, Xing S. Adherence to antiretroviral therapy in managed care members in the United States: a retrospective claims analysis. J Managed Care Pharm. 2014;20(1):86–92. doi:10.18553/jmcp.2014.20.1.86
   Google Scholar
• Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV Treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019;13:475–490. doi:10.2147/PPA.S19273531040651
   PubMed Web of Science ®Google Scholar
• Kim MJ, Kim SW, Chang HH. Comparison of antiretroviral regimens: adverse effects and tolerability failure that cause regimen switching. Infect Chemother. 2015;47(4):231–238. doi:10.3947/ic.2015.47.4.23126788406
   PubMed Web of Science ®Google Scholar
• Davy-Mendez T, Erron JJ, Zakharova O, Wohl DA, Napravnik S. Increased persistence of initial treatment for HIV infection with modern antiretroviral therapy. J Acquir Immune Defic Syndr. 2017;76(2):111–115. doi:10.1097/QAI.000000000000148128628528
   PubMed Web of Science ®Google Scholar
• Cohen C, Meyers J, Davis K. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open. 2013;3(8):e003028. doi:10.1136/bmjopen-2013-003028
   PubMed Web of Science ®Google Scholar
• Wood E, Hogg R, Yip B, Harrigan P, O’Shaughnessy M, Montaner J. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 109 cells/L. Ann Intern Med. 2003;139(10):810. doi:10.7326/0003-4819-139-10-200311180-0000814623618
   PubMed Web of Science ®Google Scholar
• Fielden S, Rusch M, Yip B, et al. Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral Naïve patients started on HAART. J Int Assoc Physicians AIDS Care. 2008;7(5):238–244. doi:10.1177/1545109708323132
   Google Scholar
• Kitahata M, Reed S, Dillingham P, et al. Pharmacy-based assessment of adherence to HAART predicts virologic and immunologic treatment response and clinical progression to AIDS and death. Int J STD AIDS. 2004;15(12):803–810. doi:10.1258/095646204256366615601486
   PubMed Web of Science ®Google Scholar
• Bangsberg D, Perry S, Charlebois E, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15(9):1181–1183. doi:10.1097/00002030-200106150-0001511416722
   PubMed Web of Science ®Google Scholar
• Meyers J, Mugavero M, Davis K. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One. 2012;7(2):e31591. doi:10.1371/journal.pone.003159122384040
   PubMed Web of Science ®Google Scholar
• Lam W, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:217047. doi:10.1155/2015/21704726539470
   PubMed Web of Science ®Google Scholar
• Schaecher K. The importance of treatment adherence in HIV. Am J Manag Care. 2013;19(12 Suppl):s231–7.24495293
   PubMed Web of Science ®Google Scholar
• Raffi F, Yazdanpanah Y, Fagnani F, Laurendeau C, Lafuma A, Gourmelen J. Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database. J Antimicrob Chemother. 2015;70(7):2121–2128. doi:10.1093/jac/dkv08325904729
   PubMed Web of Science ®Google Scholar
• Bae J, Guyer W, Grimm K, Altice F. Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research. AIDS. 2011;25(3):279–290. doi:10.1097/QAD.0b013e328340feb021239892
   PubMed Web of Science ®Google Scholar
• Robbins GK, Cohn SE, Harrison LJ, et al. Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251. HIV Clin Trials. 2016;17(4):165–172. doi:10.1080/15284336.2016.118975427347650
   PubMed Web of Science ®Google Scholar
• Bardeguez AD, Lindsey JC, Shannon M, et al. Adherence to antiretrovirals among US women during and after pregnancy. J Acquir Immune Defic Syndr. 2008;48(4):408–417. doi:10.1097/QAI.0b013e31817bbe8018614923
   PubMed Web of Science ®Google Scholar
• Tennant SJ, Hester EK, Caulder CR, Lu K, Bookstaver PB. Adherence among rural HIV-infected patients in the deep-south: a comparison between single-tablet and multi-tablet once-daily regimens. J Int Assoc Provid AIDS Care. 2015;4(1):64–71. doi:10.1177/2325957414555228
   Google Scholar
• Clay PG, Nag S, Graham CM, Narayanan S. Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens. Medicine. 2015;94(42):e1677. doi:10.1097/MD.000000000000087426496277
   PubMed Web of Science ®Google Scholar
• Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36(3):808–816. doi:10.1097/00126334-200407010-0000715213564
   PubMed Web of Science ®Google Scholar
• Juday T, Grimm K, Zoe-Powers A, Willig J, Kim E. A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States. AIDS Care. 2011;23(9):1154–1162. doi:10.1080/09540121.2010.54388421500025
   PubMed Web of Science ®Google Scholar
• Asad S, Hulgan T, Raffanti SP, Daugherty J, Ray W, Sterling TR. Sociodemographic factors predict early discontinuation of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors. J Natl Med Assoc. 2008;100(12):1417–1424. doi:10.1016/s0027-9684(15)31541-819110909
   PubMed Web of Science ®Google Scholar
• Hughes AJ, Mattson CL, Scheer S, Beer L, Skarbinski J. Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States. J Acquir Immune Defic Syndr. 2014;66(1):80–89. doi:10.1097/QAI.000000000000008424326608
   PubMed Web of Science ®Google Scholar
• Angione SA, Cherian SM, Ozdener AE. A review of the efficacy and safety of Genvoya® (elvitegravir, cobicistat, emtricitabine, and tenofoviralafenamide) in the management of HIV-1 infection. J Pharm Pract. 2018;31(2):216–221. doi:10.1177/089719001771051928558493
   PubMed Web of Science ®Google Scholar
• DeJesus E, Haas B, Segal-Maurer S, et al. Superior efficacy and improved renal and bone safety after switching from a tenovofir disoproxil fumarate- to a tenofovir aladenamide-based regimen through 96 weeks of treatment. AIDS Res Hum Retroviruses. 2018;34(4):337–342. doi:10.1089/AID.2017.020329368537
   PubMed Web of Science ®Google Scholar
• Hagins D, Orkin C, Daar ES, et al. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. HIV Med. 2018;19(10):724–733. doi:10.1111/hiv.1266430101539
   PubMed Web of Science ®Google Scholar
• Calin R, Hamimi C, Lambert-Niclot S, et al. Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir. AIDS. 2016;30(5):761–769. doi:10.1097/QAD.000000000000098726730568
   PubMed Web of Science ®Google Scholar